Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment

B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study

(2011) Jérémie Sellam et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

(2010) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood

(2010) Lisa G. M. van Baarsen et al.   ARTHRITIS AND RHEUMATISM

Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF

(2010) Laura E. DeForge et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Progression in early rheumatoid arthritis

(2009) Bernard Combe   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Antibodies to citrullinated proteins in arthritis: pathology and promise

(2009) Lars Klareskog et al.   CURRENT OPINION IN RHEUMATOLOGY

Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation

(2008) Y K O Teng et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-CD20 therapy in patients with rheumatoid arthritis: Predictors of response and B cell subset regeneration after repeated treatment

(2008) Petra Roll et al.   ARTHRITIS AND RHEUMATISM

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

(2008) Shouvik Dass et al.   ARTHRITIS AND RHEUMATISM

Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis

(2008) Gregg J. Silverman et al.   IMMUNOLOGICAL REVIEWS

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET